logo
Plus   Neg
Share
Email

Eli Lilly Reports Positive Results From Phase 3b/4 Study Of Taltz - Quick Facts

Eli Lilly and Company (LLY) said Taltz demonstrated effectiveness in improving the signs and symptoms of active psoriatic arthritis in a Phase 3b/4 SPIRIT-Head-to-Head study. The trial demonstrated that Taltz was more effective than Humira in simultaneously achieving both joint and skin responses after 24 weeks of treatment. Topline results from the study were announced last year.

A total of 566 patients were enrolled in the study. Taltz also met the key secondary endpoints. The safety data were consistent with previously reported results.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. (AAPL) unveiled a 16-inch MacBook Pro laptop with a larger screen and redesigned keyboard. It is the first major update since the MacBook Pro line was revamped three years ago. The company has moved from a 15-inch screen to a higher-resolution 16-inch screen. Facebook has launched its new payment platform called 'Facebook Pay' in the U.S., joining other tech giants like Google and Apple that have their own payment platforms. The new service will be available across Facebook and its associated apps - Messenger, Instagram and WhatsApp, the social media giant said in a blog post. The payment service supports most major credit and debit cards. Amneal Pharmaceuticals, LLC recalled certain lots of heartburn medication Ranitidine in the form of tablets and syrup for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine, above levels established by the U.S. Food and Drug Administration or FDA. The generic and specialty pharma company is recalling 94 lots of Ranitidine tablets and Syrup.
Follow RTT
>